Serum Aβ Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort

Laila Abdullah, Cheryl Luis, Daniel Paris, Benoit Mouzon, Ghania Ait-Ghezala, Andrew P Keegan, Duolao Wang, Fiona Crawford, and Michael Mullan
Clinical studies designed to understand and treat mild cognitive impairment (MCI) and Alzheimer’s disease (AD) endure challenges such as a lack of biomarkers for therapeutic outcome. One promising avenue in this sphere is the evaluation of peripheral beta-amyloid (Aβ) levels. However, variations in Aβ levels have been linked with vascular risk factors and the medications used to treat them, a fact which could downgrade the predictive utility of this protein. Using a longitudinal study design, Abdullah et al. determine whether a) systolic blood pressure, total cholesterol, triglycerides, serum creatinine or b) APOE, statin and anti-hypertensives influenced the predictive value of serum Aβ for MCI/AD over two years. They found that, once adjusted for vascular risk factors and medications, Aβ levels and their derived ratios are sensitive predictors of conversion to MCI/AD. This work could significantly impact how Aβ is used to predict clinical outcomes in MCI and AD.

View article: PDF

Posted by MolMed Editor on Dec 4, 2009 12:00 AM CST